[Form 4] VivoSim Labs, INC. Insider Trading Activity

Rhea-AI Filing Summary

VivoSim Labs, Inc. (VIVS) filed a Form 4 reporting a director’s change in ownership. On 11/17/2025, the director reported a transaction involving 3,266 shares of common stock at $2.2351 per share, and reported 0 shares beneficially owned following the transaction, held directly.

The company notes that, effective March 20, 2025, it completed a 1-for-12 reverse stock split of its common stock, and all share amounts in this filing already reflect that split.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gobel David

(Last) (First) (Middle)

11555 SORRENTO VALLEY ROAD SUITE 100

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VivoSim Labs, INC. [ VIVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/17/2025		S		3,266	A	$2.2351	0(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Effective on March 20, 2025, the Issuer conducted a reverse stock split of its common stock at a ratio of 1-for-12 (the "Reverse Split"). All share numbers reported herein give effect to the Reverse Split.

	/s/ Keith Murphy, attorney-in-fact	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did VivoSim Labs (VIVS) report on this Form 4?

The Form 4 reports a director’s transaction on 11/17/2025 involving 3,266 shares of VivoSim Labs common stock at $2.2351 per share, with 0 shares beneficially owned afterward.

What is the reporting person’s relationship to VivoSim Labs (VIVS)?

The reporting person is identified as a Director of VivoSim Labs, Inc., and the filing is made by one reporting person.

How many VivoSim Labs (VIVS) shares does the insider report owning after the transaction?

Following the reported transaction, the Form 4 states that the reporting person beneficially owns 0 shares of VivoSim Labs common stock, held directly.

At what price did the reported VivoSim Labs (VIVS) share transaction occur?

The transaction in VivoSim Labs common stock was reported at a price of $2.2351 per share for the 3,266 shares involved.

How did VivoSim Labs’ reverse stock split affect the share numbers in this Form 4?

VivoSim Labs completed a 1-for-12 reverse stock split of its common stock effective March 20, 2025, and the Form 4 states that all share numbers reported give effect to the reverse split.

Does this VivoSim Labs (VIVS) Form 4 involve derivative securities?

The Form 4 includes a table for derivative securities, but no derivative transactions or holdings are reported; only the common stock transaction is detailed.